NCT04469075Active, not recruitingPhase 2
Clindamycin and Triamcinolone in People With Glioblastoma to Prevent Skin-Related Side Effects of Tumor Treating Fields
The PROTECT Study: A Phase II, Open-Label Trial of PROphylactic Skin Toxicity ThErapy With Clindamycin and Triamcinolone in Glioblastoma Patients Treated With Tumor Treating Fields
Source: ClinicalTrials.gov · Last updated 10 Aug 2026
Brief summary (registry, in English)
The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.
- Status (registry)
- Active, not recruiting
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 48 (actual)
- First submitted
- 10 Jul 2020
- Start date
- 9 Jul 2020
- Primary completion date
- 31 Jul 2027
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Diseases
- Glioblastoma
- NCT number
- NCT04469075
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 48
- From 9 Jul 2020 to the primary completion date, 31 Jul 2027
- 8 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Use of concurrent topical therapy to the scalp for another dermatologic condition
- Use of greater than 4 mg dexamethasone a day within 14 days of enrollment
Other illness
- Known history of allergy to any ingredient of the study agents
- Preexisting scalp disorders such as psoriasis or dermatitis that, in the opinion of the investigator, will affect the grading of skin adverse events, confirmed by enrolling institution.
- Active, uncontrolled infection requiring systemic or oral antibiotic therapy within 14 days of enrollment
- Malignant glioma
Other
- Pregnant Women
Who the study is looking for
- Age ≥18 years
- Diagnosis of newly diagnosed or recurrent GBM with plan to initiate treatment with TTFields with or without systemic therapy, confirmed by the enrolling institution
- Able to self-administer topical interventions or has available another person who can apply the topical agents
- Treatment with TTF should be initiated within 7 days of planned initiation on this trial.
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (8)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Tufts Medical Center Coordinator of this site? Confirm its status | Boston | United States | Unknown status |
| University of Cincinnati Medical Center Coordinator of this site? Confirm its status | Cincinnati | United States | Unknown status |
| Northwestern University Coordinator of this site? Confirm its status | Evanston | United States | Unknown status |
| Hackensack Meridian Health Coordinator of this site? Confirm its status | Hackensack | United States | Unknown status |
| Memorial Sloan Kettering Cancer Center Suffolk - Hauppauge (All Protocol Activities) Coordinator of this site? Confirm its status | Hauppauge | United States | Unknown status |
| Memorial Sloan-Kettering Cancer Center Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Columbia University Coordinator of this site? Confirm its status | New York | United States | Unknown status |
| Washington University School of Medicine Coordinator of this site? Confirm its status | St Louis | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.